Janus kinases in leukemia

Tutkimustuotos: Katsausartikkelivertaisarvioitu

1 Sitaatiot (Scopus)

Abstrakti

Janus kinases (JAKs) transduce signals from dozens of extracellular cytokines and function as critical regulators of cell growth, differentiation, gene expression, and immune responses. Deregulation of JAK/STAT signaling is a central component in several human diseases including various types of leukemia and other malignancies and autoimmune diseases. Different types of leukemia harbor genomic aberrations in all four JAKs (JAK1, JAK2, JAK3, and TYK2), most of which are activating somatic mutations and less frequently translocations resulting in constitutively active JAK fusion proteins. JAKs have become important therapeutic targets and currently, six JAK inhib-itors have been approved by the FDA for the treatment of both autoimmune diseases and hemato-logical malignancies. However, the efficacy of the current drugs is not optimal and the full potential of JAK modulators in leukemia is yet to be harnessed. This review discusses the deregulation of JAK-STAT signaling that underlie the pathogenesis of leukemia, i.e., mutations and other mechanisms causing hyperactive cytokine signaling, as well as JAK inhibitors used in clinic and under clinical development.

AlkuperäiskieliEnglanti
Artikkeli800
Sivut1-20
Sivumäärä20
JulkaisuCancers
Vuosikerta13
Numero4
DOI - pysyväislinkit
TilaJulkaistu - 2021
OKM-julkaisutyyppiA2 Katsausartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

  • Jufo-taso 1

!!ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Sormenjälki

Sukella tutkimusaiheisiin 'Janus kinases in leukemia'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä